目的 探究連花清瘟膠囊聯(lián)合阿奇霉素治療肺炎支原體肺炎的臨床治療療效及其對(duì)免疫功能的影響。方法 選取2018年3月—2019年5月河南省人民醫(yī)院診斷為肺炎支原體肺炎患者96例作為研究對(duì)象，按就診順序根據(jù)隨機(jī)數(shù)字法分為對(duì)照組和觀察組，每組各48例。對(duì)照組靜脈滴注注射用阿奇霉素，0.5 g/次，1次/d。觀察組在對(duì)照組的基礎(chǔ)上口服連花清瘟膠囊，4粒/次，3次/d。兩組均連續(xù)治療5 d。觀察兩組患者的臨床療效，比較兩組治療前后的肺功能和免疫功能指標(biāo)水平。結(jié)果 治療后，對(duì)照組和觀察組的總有效率分別為83.33%、95.83%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者第1秒用力呼氣容積（FEV₁）和用力肺活量（FVC）水平均顯著升高（P<0.05），且觀察組肺功能指標(biāo)均顯著高于對(duì)照組（P<0.05）。治療后，兩組免疫球蛋白（Ig）A、IgG、IgM和CD4⁺水平均顯著升高，CD8⁺顯著降低（P<0.05）；治療后，觀察組患者IgG、IgM和CD8⁺水平顯著低于對(duì)照組，IgA和CD4⁺水平高于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 連花清瘟膠囊聯(lián)合阿奇霉素治療肺炎支原體肺炎能顯著提高臨床療效，改善血清中免疫因子表達(dá)水平，減少不良反應(yīng)的發(fā)生，具有較高的臨床應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Lianhua Qingwen Capsules combined with azithromycin in treatment of mycoplasma pneumoniae and its influence on immune function. Methods A total of 96 patients with mycoplasma pneumoniae pneumonia in People's Hospital of Zhengzhou from March 2018 to May 2019 were selected as study subjects. According to the order of admission, they were divided into control group and observation group according to the random number method, with 48 patients in each group. Patients in the control group were iv administered with Azithromycin for Injection, 0.5 g/time, once daily. Patients in the observation group were po administered with Lianhua Qingwen Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 5 d. The clinical efficacy in two groups was observed, and the lung function and immune function indexes before and after treatment were compared. Results After treatment, the total effective rate of the control group and the observation group was 83.33% and 95.83%, respectively, and the difference between two groups was statistically significant (P<0.05). After treatment, the levels of FEV₁ and FVC in two groups were significantly increased (P<0.05), and the levels of lung function indexes in the observation group were significantly higher than those in the control group (P<0.05). After treatment, IgA, IgG, IgM, and CD4⁺ levels in two groups were significantly increased, while CD8⁺ levels were significantly decreased (P<0.05). After treatment, IgG, IgM, and CD8⁺ levels in the observation group were significantly lower than those in the control group, but IgA and CD4⁺ levels were higher than those in the control group, with statistically significant differences (P<0.05). Conclusion Lianhua Qingwen Capsules combined with azithromycin in treatment of mycoplasma pneumonia can significantly improve the clinical efficacy, improve the expression level of immune factors in serum, reduce the occurrence of adverse reactions, has a high clinical application value.

R974

國(guó)家自然科學(xué)基金資助項(xiàng)目（No.81273877）